Target population: Patients with Parkinson's disease
Measures: Tremor, Bradykinesia, Cognition
Clinical support: Diagnostic, Monitoring, Prediction
nQ is a computational biotechnology company that uses digital phenotyping through Artificial Intelligence-aided analysis of personal device interactions to develop digital biomarkers for neurodegenerative diseases, like Parkinson's disease (PD) and Alzheimer’s disease (AD) in early and newly diagnosed/untreated stages.
Early data from the AD trial has advanced to yield early and promising results measuring cognitive decline and delineating PD and AD symptomatology. In prodromal stages of neurodegenerative diseases such as PD, digital biomarkers offer possibility of detecting actual subclinical symptoms prior to traditional methods of assessing phenoconversion and in combination with biochemical markers which often predict disease risk but not timing. Some key advantages of our digital biomarkers include:
- (1) Continuous, longitudinal, remote, real world quantification of psychomotor symptoms
- (2) Patients are not burdened with completing structured tasks or clinic visits for data collection. Patients use their personal devices as they normally would, and data is collected passively and transparently, often 24/7
- (3) Patient privacy and security is ensured at each step of algorithm. Biomarkers perform even though content of what patients type on their personal devices kept confidential and secure.
Languages: English, Spanish, with coming 2022 releases in German, Japanese
Platforms: Desktop, Tablet, Mobile Phone (iPhone, Android, Other)
User interfaces: No traditional interface; Passive data collection of keystroke and touchscreen interaction.
- Unlimited maximum number of subjects
- Able to generate a database
- Joint ownership of input data (nQ retains de-identified data)
- Data stored in Amazon Web Services
- Control data available
- Support for usage/test-setting/analysis available. Additional cost
For more information:
Teresa Arroyo Gallego, PhD